Ferroptosis: An emerging strategy for managing epithelial ovarian cancer
Alarcón-Veleiro, C; López-Calvo, I; Berjawi, L; Lucio Gallego, Sergio; Mato Basalo, Rocío; Quindós Varela, María; Lesta Mellid, Rocío; Santamaría Cainzos, Isabel; Varela-Rodríguez, S; Fraga Rodríguez, Máximo Francisco; Quintela, M; Vizoso-Vázquez, A; Arufe Gonda, Mº del Carmen; Fafián Labora, Juan A

Identifiers
Identifiers
Files view or download
Files view or download
Date issued
2025-04-29Journal title
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Type of content
Artigo
Abstract
[EN] Ferroptosis is a regulated form of cell death characterised by iron-dependent lipid peroxidation, a process intricately linked to cellular redox homeostasis. This form of cell death is induced by the accumulation of intracellular iron and the subsequent generation of reactive oxygen species (ROS), which leads to lipid peroxidation and ultimately cell death. Ferroptosis is distinct from traditional forms of cell death, such as apoptosis, and holds significant therapeutic potential, particularly in cancers harboring rat sarcoma virus (RAS) mutations, such as epithelial ovarian cancer (EOC). EOC is notoriously resistant to conventional therapies and is associated with a poor prognosis. In this review, we examine recent progress in the understanding of ferroptosis, with a particular focus on its redox biology and the complex regulatory networks involved. We also propose a novel classification system for ferroptosis modulators, grouping them into six categories (I, II, III, IV, V and VI) based on their mechanisms of action and their roles in modulating cellular redox status. By refining these categories, we aim to provide deeper insights into the role of ferroptosis in cancer biology, especially in EOC, and to identify potential therapeutic avenues. We propose that further investigation of ferroptosis in the context of redox biology could reveal novel biomarkers and therapeutic targets, offering promising strategies to overcome resistance mechanisms and improve clinical outcomes for patients with EOC and other treatment-resistant cancers.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional
